• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $NEOG

    Neogen Corporation

    Subscribe to $NEOG
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.

    IPO Year: 1989

    Exchange: NASDAQ

    Website: neogen.com

    Recent Analyst Ratings for Neogen Corporation

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    See more ratings

    Neogen Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen upgraded by William Blair

    William Blair upgraded Neogen from Mkt Perform to Outperform

    11/22/22 8:02:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Piper Sandler initiated coverage on Neogen with a new price target

    Piper Sandler initiated coverage of Neogen with a rating of Neutral and set a new price target of $25.00

    7/12/22 7:33:12 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wainer Andrea F was granted 6,090 shares (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    6/4/25 4:08:39 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Wainer Andrea F

    3 - NEOGEN CORP (0000711377) (Issuer)

    6/4/25 4:01:51 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Financial Officer Naemura David H. was granted 52,724 shares, increasing direct ownership by 86% to 114,158 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    6/4/25 12:54:50 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Rocklin Amy M was granted 43,585 shares, increasing direct ownership by 118% to 80,436 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    6/4/25 11:43:14 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Accounting Officer Moylan John Patrick was granted 26,362 shares, increasing direct ownership by 264% to 36,362 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    6/4/25 11:29:13 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Accounting Officer Moylan John Patrick exercised 4,558 shares at a strike of $5.15 and covered exercise/tax liability with 1,603 shares, increasing direct ownership by 30% to 12,955 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/2/25 1:48:58 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CEO Adent John Edward exercised 2,112 shares at a strike of $5.16, increasing direct ownership by 0.78% to 271,276 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/29/25 1:39:59 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operating Officer Jones Douglas Edward exercised 845 shares at a strike of $5.16 and covered exercise/tax liability with 291 shares, increasing direct ownership by 0.78% to 71,713 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/29/25 1:34:22 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Rocklin Amy M exercised 564 shares at a strike of $5.16, increasing direct ownership by 2% to 36,851 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/29/25 1:29:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Establishes Relationship with Biomatter

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has entered into an arrangement with Biomatter, a leading enzyme design company, to leverage Biomatter's proprietary Intelligent Architecture™ platform and Neogen's expertise in the field of analytical development and technology to create new enzyme-based products. Biomatter's Intelligent Architecture™ platform, based on AI and Physical modelling, enables the design of enzymes with unique capabilities, dramatically expanding how they can be used in food safety related applications. "This relationship marks a significant step forward in advancing food security," said Dr. Jason Lilly,

    8/11/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter 2025 Results

    Revenue of $225.5 million. Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. Adjusted Net Income1 of $11.3 million; $0.05 per diluted share. Adjusted EBITDA1 of $40.6 million. 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2025. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief Executive Officer. "We believe the Food Safety end mar

    7/29/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Expands its Pathogen Portfolio and Environmental Monitoring Solutions with a New Rapid Test for Listeria

    Company Unveils Listeria Right Now™ at IAFP 2025, Delivering Actionable Results in Two Hours Neogen Corporation (NASDAQ:NEOG) today announced the launch of Molecular Detection Assay - Listeria Right Now™, a rapid, enrichment-free solution for detecting Listeria species in the environment. The new tool is being introduced at the 2025 International Association for Food Protection (IAFP) Annual Meeting, taking place July 27–30 at the Huntington Convention Center in Cleveland, Ohio. With a time-to-result of approximately two hours, Listeria Right Now helps enable food safety professionals to make faster, more informed sanitation decisions without compromising accuracy or requiring complex l

    7/28/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Completes Sale of Cleaners & Disinfectants Business to Kersia Group

    Neogen Corporation (NASDAQ:NEOG), a global leader in food safety solutions, announced today it has completed the divestiture of its global cleaners and disinfectants business to Kersia Group for $130 million in cash at closing, plus contingent consideration tied to future performance of the business. "The completion of this transaction marks an important step forward in simplifying and enhancing the strategic focus on our core business," said John Adent, President and Chief Executive Officer of Neogen. "We are confident that Kersia is the right long-term owner for this business and its team, and we thank them for their collaboration throughout the process." Net proceeds from the transac

    7/18/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 29, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 65461 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusio

    7/8/25 4:05:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Launches Second Edition Environmental Monitoring Handbook to Elevate Food Safety Practices

    Industry-leading resource developed with Cornell University's College of Agriculture and Life Sciences (CALS) and 20+ global experts provides a framework for building and enhancing environmental monitoring programs In recognition of World Food Safety Day, Neogen® Corporation (NASDAQ:NEOG) today announced the release of the Second Edition Neogen Environmental Monitoring Handbook, a comprehensive resource designed to help food and beverage manufacturers strengthen food safety programs and reduce contamination risks. The updated guide introduces critical new insights on validating risk-based controls, conducting root cause analysis, and leveraging data for continuous improvement, providing f

    6/5/25 8:30:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® to Participate in the 45th Annual William Blair Growth Stock Conference

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that the Company will participate in the 45th Annual William Blair Growth Stock Conference in Chicago, Illinois, on Wednesday, June 4, 2025. David Naemura, Neogen's Chief Financial Officer and Chief Operating Officer, will present at 8:40 a.m. Central Time. To access the event webcast link, please visit the Events & Presentations section at neogen.com/investor-relations/events-presentations. About Neogen Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology,

    5/21/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Sale of Cleaners & Disinfectants Business

    Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global cleaners and disinfectants business to Kersia Group ("Kersia"), a global leader in biosecurity, disinfection and hygiene solutions, for $130 million in cash at closing plus contingent consideration tied to the future performance of the business. The transaction is expected to be accretive to margins and close in the first quarter of the Company's 2026 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds will be used to fully repay the $100 million drawn on the Company's revolving credit facili

    4/21/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation SEC Filings

    View All

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    8/14/25 4:18:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Neogen Corporation

    10-K - NEOGEN CORP (0000711377) (Filer)

    7/30/25 1:33:06 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    7/29/25 7:01:34 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    7/24/25 9:04:07 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 11-K filed by Neogen Corporation

    11-K - NEOGEN CORP (0000711377) (Filer)

    6/24/25 3:41:28 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    6/4/25 8:59:08 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SD filed by Neogen Corporation

    SD - NEOGEN CORP (0000711377) (Filer)

    5/29/25 9:26:37 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    5/14/25 1:49:07 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    5/13/25 4:11:40 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    4/22/25 4:45:23 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 4:32:35 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 2:45:19 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Boehm William T bought $26,175 worth of shares (5,000 units at $5.24), increasing direct ownership by 16% to 36,214 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/24/25 3:34:30 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Borel James C bought $171,290 worth of shares (35,000 units at $4.89), increasing direct ownership by 137% to 60,474 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/24/25 11:18:56 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Rocklin Amy M bought $62,375 worth of shares (12,500 units at $4.99), increasing direct ownership by 53% to 36,287 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/23/25 10:46:08 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Capello Jeffrey D bought $100,217 worth of shares (20,712 units at $4.84), increasing direct ownership by 350% to 26,629 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/22/25 3:37:21 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Tobin James P bought $47,268 worth of shares (10,000 units at $4.73), increasing direct ownership by 36% to 37,474 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/22/25 11:46:10 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Rodriguez Rafael A bought $34,306 worth of shares (7,474 units at $4.59), increasing direct ownership by 100% to 14,948 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/22/25 11:43:06 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Accounting Officer Moylan John Patrick bought $50,700 worth of shares (10,000 units at $5.07) (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/10/25 10:12:42 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Leadership Updates

    Live Leadership Updates

    View All

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces CEO Transition

    Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

    4/9/25 7:01:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Neogen Announces the Appointment of New Board Member

    LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

    10/1/24 8:45:00 AM ET
    $NEOG
    $QGEN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Neogen Announces the Appointment of Two New Board Members

    Board of Directors expanded in conjunction with the closing of the 3M Food Safety transaction LANSING, Mich., Sept. 12, 2022 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG), a leader in food and animal safety, announced today that it has appointed two new members to its Board of Directors: Jeffrey Capello and Aashima Gupta. The addition of Mr. Capello and Ms. Gupta was agreed by Neogen and 3M Company under the merger agreement for the 3M Food Safety transaction. "We are pleased to add these two experienced industry professionals to Neogen's Board of Directors," said Jim Borel, Neogen's Board Chair. "Their involvement in the global healthcare and biotechnology industries will be a significan

    9/12/22 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Financials

    Live finance-specific insights

    View All

    Neogen Announces Fourth-Quarter 2025 Results

    Revenue of $225.5 million. Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. Adjusted Net Income1 of $11.3 million; $0.05 per diluted share. Adjusted EBITDA1 of $40.6 million. 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2025. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief Executive Officer. "We believe the Food Safety end mar

    7/29/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 29, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 65461 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusio

    7/8/25 4:05:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Third-Quarter 2025 Results

    Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

    4/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Third-Quarter Earnings Release Date

    LANSING, Mich., March 20, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Wednesday, April 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing:Toll-Free - North America: 1-800-549-8228International: (+1) 646-564-2877Conference ID: 63045 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/inves

    3/20/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Preliminary¹ Second-Quarter 2025 Results

    Revenue of $231.3 million.Net loss of $456.3 million due to non-cash goodwill impairment; $(2.10) per diluted share.Adjusted Net Income2 of $24.4 million; $0.11 per diluted share.Adjusted EBITDA2 of $51.4 million.Updating full-year guidance.LANSING, Mich., Jan. 10, 2025 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the preliminary results of the second quarter ended November 30, 2024. "The second quarter reflected steady progress, as we saw improvement across the business compared to the first quarter, with core revenue growth accelerating in both of our seg

    1/10/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces Change to Second-Quarter Earnings Release Date

    LANSING, Mich., Jan. 2, 2025 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) announced today that, due to U.S. equity markets being closed in observance of the National Day of Mourning for former U.S. President Jimmy Carter, it will now issue its second-quarter earnings release before the opening of the market on Friday, January 10, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646)

    1/2/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces Second-Quarter Earnings Release Date

    LANSING, Mich., Dec. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on Thursday, January 9, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation Q2 FY25 Earnings Call. The live webcast can be accessed through Neogen's Investor Relation

    12/19/24 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces First-Quarter 2025 Results

    Revenue of $217.0 million.Net loss of $12.6 million; $(0.06) per diluted share.Adjusted Net Income of $14.4 million; $0.07 per diluted share.Adjusted EBITDA of $43.7 million.Maintaining full-year guidance.LANSING, Mich., Oct. 10, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the results of the first quarter ended August 31, 2024. "During the first quarter, the focus of our teams shifted from managing through the initial complexity of exiting the transition service agreements from the 3M transaction to gaining market share," said John Adent, Neogen's Pre

    10/10/24 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces First-Quarter Earnings Release Date

    LANSING, Mich., Sept. 19, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG) will issue its first-quarter earnings release before the opening of the market on Thursday, October 10, 2024. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen Corporation First Quarter 2025 Earnings Call. The live webcast can be accessed through Neogen's Inves

    9/19/24 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter 2024 Results

    Revenue of $236.8 million.Net loss of $5.4 million; $(0.02) per diluted share.Adjusted Net Income of $22.4 million; $0.10 per diluted share.Adjusted EBITDA of $53.0 million.LANSING, Mich., July 30, 2024 /PRNewswire/ -- Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2024. "After crossing multiple significant integration milestones in the third quarter related to the integration of the former 3M Food Safety business, progress continued on multiple fronts in the fourth quarter," said John Adent, Neogen's President and Chief Execut

    7/30/24 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/9/24 11:58:12 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    1/30/24 10:20:33 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/14/23 10:47:37 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/14/23 10:34:15 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/9/23 11:27:43 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/8/23 1:12:20 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    10/11/22 9:52:04 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care